Author:
Weber C.,Schallner J.,Von Der Hagen M.
Subject
Neurology (clinical),Developmental Neuroscience,General Medicine,Pediatrics, Perinatology and Child Health
Reference48 articles.
1. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy;Finkel;N Engl J Med,2017
2. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial;Day;Lancet Neurol,2021
3. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial;McDonald;Lancet,2017
4. Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy;Straub;Lancet Neurol,2016
5. The Identification of Novel Biomarkers Is Required to Improve Adult SMA Patient Stratification;Smeriglio;Diagnos Treatm J Pers Med,2020